An open label, randomized control study for the comparison of effectiveness between biguanides and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes - An open label, randomized control study for the comparison of effectiveness between biguanides and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes

Kanazawa University Graduate School of Medical Science0 个研究点目标入组 80 人开始时间: 2013年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Hypersensitivity to or contraindication of biguanides and alogliptin 2.Type 1 diabetes, gestational diabetes mellitus, secondary diabetes 3.Medical history and/or complication of diabetic ketoacidosis 4.Medical history and/or complication of severe hypoglycemia 5.Severe infection, before and after surgery, patients with severe trauma 6.Patients treated with metformin or alogliptin within 4 weeks before the start of treatment 7.Patients introduced or those undergoing systemic administration of steroids 8.unstable glycemic control 9.Patients with severe renal impairment, including patients requiring hemodialysis or peritoneal dialysis (Less than more than more than Ccr 30mL / expression Cockcraft, man serum creatinine >2.5mg/dL, woman serum creatinine >2.0mg/dL) 10.Severe hypertension (systolic blood pressure > 100mmHg or diastolic blood pressure > 160mmHg) 11.The patients with severe heart disease of congestive heart failure, myocardial infarction, unstable angina within one year onset 12.Proliferative retinopathy or macular edema requiring treatment 13.History of malignancy or the treatment of malignancy within 1 year 14.Serious complications (Grade 3 classification as a guide to adverse drug reactions Ministry of Health, Labour and Welfare) 15.During pregnancy and lactation. 16.Other cases physicians sharing test was deemed inappropriate as the subject of the study or investigator.

发起方

Kanazawa University Graduate School of Medical Science